指南与共识毛发、甲与色素性疾病

雄激素性脱发治疗循证指南(S3短版)

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2017-11-27

欧洲皮肤病论坛基于系统文献研究评估现有雄激素性脱发治疗方案的疗效,并通过共识会议形成治疗推荐,为皮肤科医生选择有效安全的疗法提供循证工具。指南覆盖男女雄激素性脱发患者。

要点

  • 雄激素性脱发影响高达80%白人男性和42%女性,随年龄增长频率增加。
  • 指南基于系统文献研究评估现有治疗方案的疗效。
  • 治疗推荐通过共识会议形成,旨在帮助选择有效安全疗法。

核心结论

  • 指南为雄激素性脱发患者选择有效且安全的治疗提供循证工具。

研究设计与样本

  • 欧洲皮肤病论坛发起项目,基于系统文献研究评估现有治疗方案疗效,并通过共识会议形成治疗推荐。

主要发现

  • 雄激素性脱发是最常见的脱发疾病,影响男性和女性,初始体征通常在青少年时期出现,导致进行性模式性脱发。
  • 其频率随年龄增长而增加,影响高达80%的白人男性和42%的女性。
  • 患者可能经历显著的生活质量损害。

临床怎么用

  • 皮肤科医生可依据该循证指南为雄激素性脱发患者选择有效且安全的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2017. PMID: 29178529. doi:10.1111/jdv.14624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。